First Midwest Bank Trust Division lowered its stake in shares of Gilead Sciences Inc. (NASDAQ:GILD) by 4.4% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 84,360 shares of the biopharmaceutical company’s stock after selling 3,869 shares during the period. Gilead Sciences comprises about 0.9% of First Midwest Bank Trust Division’s portfolio, making the stock its 21st largest position. First Midwest Bank Trust Division’s holdings in Gilead Sciences were worth $7,038,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently made changes to their positions in GILD. Bank of Montreal Can acquired a new stake in shares of Gilead Sciences during the second quarter worth approximately $427,750,000. Investec Asset Management LTD acquired a new stake in shares of Gilead Sciences during the first quarter worth approximately $280,342,000. NN Investment Partners Holdings N.V. acquired a new stake in shares of Gilead Sciences during the first quarter worth approximately $180,268,000. Temasek Holdings Private Ltd raised its stake in shares of Gilead Sciences by 8.1% in the first quarter. Temasek Holdings Private Ltd now owns 13,830,516 shares of the biopharmaceutical company’s stock worth $1,270,471,000 after buying an additional 1,035,592 shares during the period. Finally, Old Mutual Global Investors UK Ltd. raised its stake in shares of Gilead Sciences by 256.3% in the second quarter. Old Mutual Global Investors UK Ltd. now owns 1,156,623 shares of the biopharmaceutical company’s stock worth $96,485,000 after buying an additional 832,028 shares during the period. 77.93% of the stock is currently owned by institutional investors.
Shares of Gilead Sciences Inc. (NASDAQ:GILD) traded down 1.07% during mid-day trading on Wednesday, reaching $73.03. The company’s stock had a trading volume of 9,981,529 shares. The firm has a market cap of $96.37 billion, a PE ratio of 6.41 and a beta of 1.10. The firm’s 50 day moving average is $78.59 and its 200 day moving average is $84.75. Gilead Sciences Inc. has a one year low of $72.92 and a one year high of $111.11.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.02 by $0.06. Gilead Sciences had a return on equity of 106.75% and a net margin of 50.50%. The business earned $7.78 billion during the quarter, compared to analyst estimates of $7.80 billion. During the same quarter in the previous year, the business earned $3.15 earnings per share. The company’s revenue for the quarter was down 5.7% compared to the same quarter last year. On average, equities analysts anticipate that Gilead Sciences Inc. will post $11.76 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Thursday, September 29th. Stockholders of record on Friday, September 16th were paid a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 2.57%. The ex-dividend date was Wednesday, September 14th. Gilead Sciences’s dividend payout ratio is presently 16.56%.
A number of analysts recently commented on GILD shares. Credit Suisse Group AG reiterated a “buy” rating and set a $120.00 price target on shares of Gilead Sciences in a report on Wednesday, June 29th. Vetr lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $95.02 target price on the stock. in a research note on Wednesday, July 6th. Leerink Swann restated a “buy” rating and issued a $120.00 target price on shares of Gilead Sciences in a research note on Tuesday, June 21st. Zacks Investment Research upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $97.00 target price on the stock in a research note on Monday, July 11th. Finally, RBC Capital Markets set a $105.00 target price on Gilead Sciences and gave the company a “buy” rating in a research note on Thursday, August 11th. Ten research analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $104.71.
In other news, EVP Paul Rutherford Carter sold 2,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, August 1st. The shares were sold at an average price of $79.81, for a total transaction of $159,620.00. Following the completion of the sale, the executive vice president now owns 64,122 shares of the company’s stock, valued at $5,117,576.82. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Kevin E. Lofton sold 3,500 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, August 24th. The shares were sold at an average price of $81.97, for a total transaction of $286,895.00. The disclosure for this sale can be found here. Insiders own 1.40% of the company’s stock.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.